IN BRIEF: SkinBioTherapeutics CEO Ashman resigns amid probe of conduct

Related news

SkinBioTherapeutics PLC - Newcastle Upon Tyne, England-based life science firm focused on skin health - Chief Executive Officer Stuart Ashman resigns after being suspended by the board ‘pending an investigation into matters relating to his conduct’. SkinBioTherapeutics provides ‘no further comment’ on the subject of the probe, saying it is ‘undertaking a full investigation, supported by its professional advisors’. Non-Executive Chair Martin Hunt becomes executive chair temporarily while the company looks for an interim CEO and then new permanent CEO. Back in October, Chief Operating Officer Simon Hewitson had left, with his duties taken over by Ashman and Finance Director Emily Bertram.

Current stock price: 14.49 pence, down 26% in London early Friday

12-month change: down 20%

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Directors

Ways to help you invest your money

Our investment accounts

Put your money to work with our range of investment accounts. Choose from ISAs, pensions, and more.

Need some investment ideas?

Let us give you a hand choosing investments. From managed funds to favourite picks, we’re here to help.

Read our expert tips and insights

Our investment experts share their knowledge on how to keep your money working hard across the markets.